OABI Stock Summary and Trading Ideas (Omniab | NASDAQ:OABI)

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Omniab trades on the NASDAQ stock market under the symbol OABI.

As of June 3, 2026, OABI stock price declined to $2.50 with 403,489 million shares trading.

OABI has a beta of 1.18, meaning it tends to be more sensitive to market movements. OABI has a correlation of 0.04 to the broad based SPY ETF.

OABI has a market cap of $362.43 million. This is considered a Small Cap stock.

Last quarter Omniab reported $14 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.04.

In the last 3 years, OABI traded as high as $6.72 and as low as $1.22.

The top ETF exchange traded funds that OABI belongs to (by Net Assets): IWM, VTI, IBB, IWN, VXF.

OABI has outperformed the market in the last year with a return of +82.5%, while the SPY ETF gained +27.8%. In the last 3 month period, OABI beat the market returning +44.5%, while SPY returned +11.1%. However, in the most recent 2 weeks OABI has underperformed the stock market by returning -3.1%, while SPY returned +1.8%.

OABI support price is $2.49 and resistance is $2.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OABI shares will trade within this expected range on the day.